

# PRELIMINARY PROGRAM

## CURRENT CHALLENGES, STRATEGIES, AND ADVANCES IN TB

WEDNESDAY, FEBRUARY 22, 2012, 1:00 pm – 5:00 pm

Advances in the Diagnosis and Treatment of Tuberculosis

THURSDAY, FEBRUARY 23, 2012

MORNING SESSION

7:00 am – 8:00 am Registration

### STOP TB MEETING: TB COLLABORATION SUCCESSES AND CHALLENGES IN TIMES OF DIMINISHING TB RESOURCES

8:00 am – 9:30 am	<b>Video Conferencing - A View of Global TB Challenges as Seen at Country Level</b>
8:00 am – 8:30 am	<b>Sustaining TB Control in Times of Fiscal Constraint: A View of Global TB Challenges As Seen at Country Level</b> <i>Dr. Nevin Wilson, The Union, New Delhi, India</i>  <b>Learning Objectives</b> Participants will be able to: 1. Increase the capacity of countries to sustain TB Control by building support through advocacy, communication and social mobilization.
8:30 am – 9:00 am	<b>Incorporating TB HIV Control Program to the Health Care System</b> <i>Pren Naidoo, Cape Town, South Africa</i>  <b>Learning Objectives</b> Participants will be able to: 1. Learn from the benefits of incorporating TB/HIV control programs to the health care system for effective TB control
9:00 am – 9:30 am	<b>Global Funding And Partner's Responsibilities Viewed from the Field</b> <i>Arnaud Trébuq, The Union, France</i>  <b>Learning Objectives</b> Participant will be able to: 1. Apply TB management system to other health care delivery to all populations especially the poor
9:30 am – 10:00 am	<b>BREAK</b>
10:15 am – 10:35 am	<b>Successful and Ongoing TB Program and Diabetes Program Collaborations</b> <i>Dr. Richard Brostrom, State of Hawaii Department of Health, HI, USA</i>  <b>Learning Objectives</b> Participant will be able to: 1. Implement collaborations between their TB programs and diabetes health care providers that will ensure diabetics with TB complete necessary treatment 2. Identify and preventively treat diabetics at high risk for TB in order to prevent the development of TB disease in these patients
10:35 am – 10:55 am	<b>Successful and Ongoing TB Program and Federally Qualified Community Health Center Collaborations</b>

	<p><b>Mr. Thomas Privett, PHA, New Jersey Department of Health and Senior Services, Trenton, NJ, USA</b></p> <p><b>Learning Objectives</b> Participant will be able to:</p> <ol style="list-style-type: none"> <li>1. Implement collaborations between their TB programs and Community Health Centers (CHCs) to ensure CHC clients will receive complete TB treatment</li> <li>2. Identify and preventively treat CHC clients at high risk for TB to prevent the development of TB disease in these patients.</li> </ol>
10:55 am – 11:15 am	<p><b>Successful and Ongoing TB and Migrant Clinician Network Collaborations</b> <b>Dr. Edward Zuroweste, Migrant Clinicians Network, State College, PA, USA</b></p> <p><b>Learning Objectives</b> Participant will be able to:</p> <ol style="list-style-type: none"> <li>1. implement collaborations between their TB programs and Migrant care providers that will ensure migrant workers with TB are effectively followed to complete necessary treatment</li> <li>2. identify and preventively treat migrant workers at high risk for TB to prevent the development of TB disease in these individuals.</li> </ol>
11:15 am – 11:35 am	<p><b>Successful and Ongoing TB Collaboration(s) in Texas</b> <b>Cynthia F. Tafolla, Grupo Sin Fronteras Binational TB Project, Harlingen, TX, USA</b></p> <p><b>Learning Objectives</b> Participant will be able to: (TBD)</p> <ol style="list-style-type: none"> <li>1. implement collaborations along the U.S./Mexico Border that will ensure that suspects and cases are referred and/or treated on both sides of the border</li> <li>2. recognize the success and challenges of managing/controlling TB across the border</li> </ol>
11:20 am – 12:00 pm	<p><b>Panel Discussion:</b> <b>Chair: Dr. Ken Castro, Centers for Disease Control and Prevention, Atlanta, GA, USA</b></p> <p><b>Learning Objectives</b> Participant will be able to:</p> <ol style="list-style-type: none"> <li>1. implement collaborations between their TB programs and other health care providers in their areas serving individuals at risk for TB that will ensure clients with TB complete necessary treatment</li> <li>2. preventively treat provider clients at high risk for TB to prevent the development of TB disease in these patients.</li> </ol>
12:00 pm – 1:00 pm	<p><b>Stop TB USA/Canada Meeting</b> <b>LUNCH BREAK</b></p>

**AFTERNOON  
SESSION**

**NURSING ASSEMBLY: A CALL TO ACTION TO SUSTAIN 'CORE NURSING VALUES' TO ACHIEVE OPTIMAL TB PATIENT OUTCOMES**

**Chairs: Ms. Kathy Hursen, Massachusetts, USA; Ms. Rose Pray, State, USA**

1:00 pm – 1:05 pm	<p><b>Introduction: Ms. Kathy Hursen and Ms. Rose Pray</b></p>
1:05 pm – 1:55 pm	<p><b>Core Nursing Values Revisited</b> <b>Ms. Virginia Williams, International Council of Nurses, Geneva, Switzerland</b></p> <p><b>Learning Objectives</b> Participants will be able to:</p> <ol style="list-style-type: none"> <li>1. discuss the impact of national and international health policies on nursing practice and what this means for investment in patient care</li> <li>2. describe core nursing values relevant to current health challenges</li> <li>3. identify what measures can be taken to ensure that core nursing values are reflected in health policy to achieve improved investment in patient care.</li> </ol>
1:55 pm – 2:35 pm	<p><b>TB Nursing Care Revisited:</b></p> <p><b>Learning Objective</b> Participants will be able to:</p> <ol style="list-style-type: none"> <li>1. use their awareness of core nursing values to identify strategies to address and/or avoid specific case problems and challenges in the care of their patients with tuberculosis</li> </ol>

1:55 pm – 2:05 pm	<b>The Heartland Regional Perspective</b> <i>Ms. Debbie Onofre, Heartland National TB Center, San Antonio, TX, USA</i>
2:05 pm – 2:15 pm	<b>The Inpatient TB Treatment Experience</b> <i>Ms. Dawn Farrell, Texas Center for Infectious Disease, San Antonio, TX, USA</i>
2:15 pm – 2:25 pm	<b>Challenge To Treat TB Along The U.S.—Mexico Border</b> <i>Ms. Catalina Navarro, Heartland National TB Center, San Antonio, TX, USA</i>
2:30 pm – 2:50 pm	<b>BREAK</b>
2:50 pm – 3:50 pm	<b>Break-Out Session</b> to draft “Call For Action”  <b>Learning Objective</b> Participants will be able to: 1. develop a call to action for sustaining ‘core nursing values’ to achieve safe optimum patient outcomes in TB treatment
3:50 pm – 4:00 pm	<b>Plenary Presentation And Wrap Up</b>

**EVENING SESSION**

4:45 pm – 5:00 pm	<b>Welcoming Remarks</b> <i>Dr. E. Jane Carter</i> <i>President, The Union-NAR</i>  <i>Ms. Ann Raftery</i> <i>Vice-President/Program Chair</i>
5:00 pm – 6:00 pm	<b>Beyond TB Lecture:</b> <i>The Union – Way Beyond TB</i> <i>Dr. Nils Billo, The Union, Paris, France</i>  <b>Learning Objectives</b> Participants will be able to: (TBD)
6:00 pm – 7:00 pm	<b>The George Comstock Lecture:</b> <i>Community Based Strategies to Address the TB, HIV and M/XDR TB Epidemics in South Africa</i>  <i>Dr. Gerald Friedland, Yale School of Public Health, New Haven, CT, USA</i>  <b>Learning Objectives</b> Participants will be able to: 1. describe the epidemiology and etiology of the South African and global epidemics of MDR and XDR TB 2. describe policies and practices in the field to reduce the epidemics’ trajectories and high levels of morbidity and mortality

**FRIDAY, FEBRUARY 24, 2012**

**MORNING SESSION**

**New Tools**

**Chairs:** *Dr. Lee Reichman, Global TB Institute, New Jersey Medical School; Dr. Ed Desmond, San Leandro, CA*

8:30 am – 9:00 am	<b>New Approaches for the Diagnosis of TB</b> <i>Dr. Rick O’Brien, Foundation for Innovative New Diagnostics; Geneva, Switzerland</i>  <b>Learning Objective</b> Participants will be able to: 1. evaluate new diagnostic tools that can improve TB detection and translate into better care at the health service delivery level to more effectively employ these new diagnostics in their practice
9:00 am – 9:30 am	<b>TB Drugs in the Pipeline: Immediate and Future Opportunities</b> <i>Dr. Mel Spigelman, Global Alliance for TB Drug Development, New York, NY, USA</i>  <b>Learning Objectives</b> Participants will be able to: 1. identify advancements in TB drug research and development that will lead to the modernization of current TB treatment practice

	2. begin to appropriately use new drugs when they become available, and discontinue the use of older, less effective and more toxic drugs to improve treatment outcomes
9:30 am – 10:00 am	<p><b>Current Vaccine Candidates for TB</b>  <i>Dr. Lewellys Barker, AERAS Global Vaccine Foundations, Rockville, MD, USA</i></p> <p><b>Learning Objectives</b>  Participants will be able to:</p> <ol style="list-style-type: none"> <li>1. assess the current state of the science, research and development for vaccines that aim to reduce the global incidence of TB and when available, incorporate into practice where appropriate</li> <li>2. provide informed input into discussions regarding the implementation of new vaccine strategies as new vaccines becomes available</li> </ol>
10:00 am – 10:30 am	<b>BREAK</b>
10:30 am – 11:00 am	<p><b>IGRAS in Practice, The Ten Year San Francisco Health Department Experience</b>  <i>Dr. Masae Kawamura, San Francisco Department of Public Health, San Francisco, CA, USA</i></p> <p><b>Learning Objectives</b>  Participants will be able to:</p> <ol style="list-style-type: none"> <li>1. discuss the experience using three generations of Quantiferon in a major municipal Public Health Practice and assess suitability of IGRA use in their practice to aide in LTBI diagnosis</li> <li>2. improve decision making about the use of IGRA testing to better serve various population groups</li> <li>3. better assess smaller and larger changes in numerical IGRA results to make well-informed decisions regarding IGRA result interpretation</li> </ol>
10:30 am – 11:00 am	<b>Panel Discussion</b>
11:40 am – 11:50 am	<b>Oral Poster Presentation #1</b>
11:50 am – 12:00 pm	<b>Oral Poster Presentation #2</b>
12:00 pm – 1:30 pm	<p><b>Annual General Meeting (Business Meeting)</b>  <b>LUNCH (Box Lunches will be provided)</b></p>

**AFTERNOON  
SESSION**

## **Guidance on Ethics of Tuberculosis Prevention, Care, and Control**

**Chairs:** *Dr. Anne Fanning, University of Alberta; Dr. Joan Mangon, Centers for Disease Control and Prevention*

1:30 pm – 2:00 pm	<p><b>Ethical Values, Human Rights and Disease Control: An Overview</b>  <i>Dr. Robert Hood, The Association for Accreditation of Human Research Protection Program, Washington, DC, USA</i></p> <p><b>Learning Objective</b>  Participants will be able to:</p> <ol style="list-style-type: none"> <li>1. make clinical and programmatic decisions based on an understanding of the relationship between ethical values, human rights and disease control</li> </ol>
2:00 pm – 2:40 pm	<p><b>The Evolution and Application of the WHO's Guidance on Ethics of TB Prevention, Care and Control</b>  <i>Dr. Andreas Reis, World Health Organization, Geneva, Switzerland</i></p> <p><b>Learning Objectives</b>  Participants will be able to:</p> <ol style="list-style-type: none"> <li>1. describe major ethical considerations associated with tuberculosis prevention, care and control and use the WHO TB Ethics Guidance Document to consider solutions to individual TB case problems and to TB control program and policy dilemmas</li> <li>2. integrate concepts from the WHO TB Ethics Guidance document when contemplating and resolving TB patient and programmatic dilemmas</li> </ol>
2:40 pm – 3:00 pm	<b>BREAK</b>
3:00 pm – 3:40 pm	<p><b>Case Presentation and Panel Discussion</b></p> <p>CASE #1:  CASE #2:  CASE #3:</p>

	<p>CASE #4:</p> <p><b>Panel Discussants:</b> <i>Dr. Lee Reichman, Global Tuberculosis Institute, New Jersey Medical School, Dr. Andreas Reiss, World Health Organization; Dr. Ross Upshur, Joint Centre for Bioethics; Dr. Robert Hood, The Association for Accreditation of Human Research Protection Programs</i></p> <p><b>Learning Objective</b> Participants will be able to:</p> <ol style="list-style-type: none"> <li>propose and integrate recommendations from the WHO TB Ethics Guidance Document to resolve TB patient and programmatic dilemmas</li> </ol>
3:40 pm – 4:00 pm	<p><b>Is your TB Control Program Ready for the Ethical Challenges?</b> <i>Dr. Lee Reichman, Global Tuberculosis, Institute New Jersey Medical School, Newark, NJ, USA</i></p> <p><b>Learning objectives</b> Participants will be able to:</p> <ol style="list-style-type: none"> <li>assess program readiness to meet common ethical challenges to service access, case management, involuntary isolation and staff training using WHO's TB Ethics Guidance documents</li> <li>identify areas in their own regional TB control program which might impede diagnosis or management of TB cases because of ethical flaws at the policy or practice level, and consider changes in policy or practice to improve access to diagnosis and/or management</li> </ol>
4:00 pm – 4:10 pm	<b>Oral Poster Presentation #3</b>
4:10 pm – 4:20 pm	<b>Oral Poster Presentation #4</b>
4:20 pm – 4:30 pm	<b>Participant Feedback: Impact of the WHO Guidance Document</b>
4:30 pm – 7:00 pm	<p><b>POSTER SESSION</b> <i>Chair: Dr. Kevin Schwartzman</i></p> <p><b>Award Ceremony</b> <b>Service Award(s)</b> <b>Lifetime Achievement Award</b></p> <p>Poster Discussion/ Light Reception</p>

**SATURDAY, FEBRUARY 25, 2012**

**MORNING SESSION**

7:30 am – 8:30 am	<b>Abstract Writing Session</b>
<p><b>CHALLENGES TO TB CONTROL – THE WAY FORWARD</b></p> <p><b>Chairs:</b> <i>Dr. Barbara Seaworth, University of Texas Health Science Center/Heartland National TB Center; Dr. Terry Baker, Jamaica National Tuberculosis Program; Dr. Lisa Armitige, Heartland National TB Center</i></p>	
8:30 am – 9:00 am	<p><b>The Impact of HIV on TB Control in the Caribbean: Successful Strategies</b> <i>Dr. Brendan Bain, University of the West Indies, Kingston, Jamaica</i></p> <p><b>Learning objectives</b> Participants will be able to:</p> <ol style="list-style-type: none"> <li>improve care for patients at risk for TB and HIV co-infection</li> <li>implement HIV and TB screening to identify and get at risk persons into care sooner</li> <li>identify several examples of programs/ strategies that have been implemented in the Caribbean Region to improve the management of HIV/TB co-infection and consider applicability of such strategies for use in their settings and in resource limited settings</li> </ol>
9:00 am – 9:30 am	<p><b>Securing Adequate Drug Supply for Each TB Patient</b> <i>Dr. Jenny Flood, California Department of Public Health, Richmond, CA, USA</i></p> <p><b>Learning Objectives</b> Participants will be able to:</p> <ol style="list-style-type: none"> <li>utilize the knowledge of limitations of supply of essential TB medications to appropriately plan for uninterrupted medication delivery for each patient</li> <li>design an appropriate treatment regimen utilizing those medications available in their</li> </ol>

	community, state or country 3. identify strategies to leverage support and gain access to needed medications to adequately treat their TB patients and improve patient and public health outcomes
9:30 am – 9:50 am	<b>BREAK</b>
9:50 am – 10:20 am	<b>Pediatric Tuberculosis – Challenges Associated with Diagnosis and Treatment</b> <i>Dr. Jeffrey Starke, Texas Children’s Hospital, Houston, TX, USA</i>  <b>Learning Objectives</b> Participants will be able to: 1. appropriately utilize diagnostics tools to improve the diagnosis of TB in children 2. identify differences in dosing/ formulation of TB drugs as they relate to pediatric patients and apply this knowledge to appropriate treatment choices
10:20 am – 10:50 am	<b>Cross Border Coordination of TB Care</b> <i>Dr. Kathleen Moser, San Diego County Health and Human Services, San Diego, CA, USA</i>  <b>Learning Objectives</b> Participants will be able to: 1. identify the various agencies who work to coordinate TB care of those leaving the U.S. to improve continuity of care for these patients 2. arrange for additional care contingencies such as identification of drug availability or expertise in the destination community for difficult TB cases transferring care across borders
10:50 am – 11:20 am	<b>Panel Discussion</b>
11:20 am – 11:30 am	<b>Oral Poster Presentation #5</b>
11:30 am – 11:40 am	<b>Oral Poster Presentation #6</b>
11:40 am – 12:00 pm	<b>Wrap-up/Summary</b> <i>Dr. Ken Castro, Centers for Disease Control and Prevention, Atlanta, GA, USA</i>
12:00 pm – 1:15 pm	<b>Latin American Liaison Committee Meeting</b> <b>LUNCH</b>

**AFTERNOON  
SESSION**

**ADVANCE IN MDR TB TREATMENT AND CONTROL**

**Chairs:** Dr. Ed Nardell, *Harvard School of Public Health/Harvard School of Medicine*; Dr. Sundari Mase, *Centers for Disease Control and Prevention*

1:30 pm – 2:00 pm	<b>Major Gaps in the Global Mechanisms for Addressing MDR-TB</b> <i>Dr. Salmaan Keshavjee, Harvard Medical School, Boston, MA, USA</i>  <b>Learning Objectives</b> Participants will be able to: 1. describe the successes and challenges that led to the restructuring of the Green Light Committee 2. discuss the current structure and process for second line drug procurement through the Global Drug Facility 3. understand the barriers to scale-up of diagnostics, drug supply and treatment delivery 4. understand alternative models to the current system
2:00 pm – 2:30 pm	<b>PETT Study Results- Implications for MDR Scale-Up</b> <i>Dr. Peter Cegielski, Centers for Disease Control and Prevention, Atlanta, GA, USA</i>  <b>Learning Objective</b> Participants will be able to: 1. discuss the results and implications of the Preserving Effective TB Treatment Study and apply these results towards patient care practices
2:30 pm – 3:00 pm	<b>MDR Contact Treatment and Fluoroquinolone Pharmacokinetic Study Results: US Affiliated Pacific Islands</b> <i>Dr. Sundari Mase, Centers for Disease Control and Prevention, Atlanta, GA, USA</i>  <b>Learning Objectives</b> Participants will be able to: 1. apply knowledge gained about the tolerability, feasibility, potential efficacy and impact of

	<p>fluoroquinolone-based treatment of MDR-LTBI to the management of MDR TB contacts</p> <p>2. evaluate the two recent pharmacokinetic studies regarding recommended dosage of levofloxacin in pediatric TB patients to apply findings to clinical practice in the pediatric patient population</p>
3:00 pm – 3:30 pm	<b>BREAK</b>
3:30 pm – 4:00 pm	<p><b>Impact of Treatment on Infectiousness of MDR TB Patients</b>  <i>Dr. Edward Nardell, Harvard School of Public Health/Harvard School of Medicine</i></p> <p><b>Learning Objective</b>  Participants will be able to:</p> <ol style="list-style-type: none"> <li>1. incorporate into practice the research findings on the impact of appropriate treatment on infectiousness of MDR TB patients to improve patient care</li> </ol>
4:00 pm – 4:30 pm	<b>Panel Discussion</b>
4:30 pm – 4:40 pm	<b>Oral Poster Presentation #7</b>
4:40 pm – 4:50 pm	<b>Oral Poster Presentation #8</b>
4:50 pm – 5:00 pm	<b>Closing Remarks/Evaluation</b>
5:30 pm – 6:30 pm	<b>Post – Conference Meeting/Planning For 2013 Conference</b>

FOR MORE INFORMATION CONTACT  
**Menn Biagtan, MD, MPH; Conference Secretariat**  
British Columbia Lung Association PHONE: 604.731.5864 FAX: 604.731.5810 E-MAIL: [biagtan@bc.lung.ca](mailto:biagtan@bc.lung.ca)